Armistice Capital, LLC's Form 4 filing
Avalo Therapeutics, Inc. (AVTX) · filed Jan 20, 2022
- Accession no.
- 0000899243-22-002693
- Filed
- Jan 20, 2022, 6:14 PM ET
- Trade date
- Jan 18-20, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $274.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Armistice Capital, LLCCIK 0001601086 | Director, 10% Owner |
| Armistice Capital Master Fund Ltd.CIK 0001633584 | Director, 10% Owner |
| Boyd StevenCIK 0001706140 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 18, 2022 | Common Stock | PPurchaseAcquired | +206,300 | $0.8833 | +$182,224.79 | 46,306,300 | Indirect | |
| Jan 19, 2022 | Common Stock | PPurchaseAcquired | +93,700 | $0.8757 | +$82,053.09 | 46,400,000 | Indirect | |
| Jan 20, 2022 | Common Stock | PPurchaseAcquired | +12,000 | $0.8507 | +$10,208.4 | 46,412,000 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.